-
2025-521642-14-00
4
2026-03-05
Multiple System Atrophy
-
2025-522873-12-00
5
2026-02-24
ER+, HER2- Advanced Breast Cancer
-
2025-521805-41-00
5
2026-02-18
Patients with HER2-positive, locally advanced or metastatic breast can
-
2025-521880-10-00
9
2026-02-16
Metastatic castrate resistant prostate cancer (mCRPC)
-
2025-522960-34-00
5
2026-02-09
Established cardiovascular disease
-
2024-515765-34-00
5
2026-02-04
English
First-line extensive-stage small-cell lung cancer (ES-SCLC)
-
2025-521636-10-00
4
2026-02-04
Progressive Forms of Multiple Sclerosis (PMS)
-
2024-517413-33-00
4
2026-02-03
Idiopathic Parkinson's Disease
-
2024-519369-24-00
5
2026-01-29
METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
-
2025-522400-24-00
10
2026-01-27
Metastatic urothelial cancer
-
2025-522683-32-00
5
2026-01-15
Early-Stage Parkinson’s Disease (PD)
-
2022-500676-59-00
4
2025-12-18
EBV-positive nasopharyngeal carcinoma
-
2024-519960-42-00
4
2025-12-11
PIK3CA-Related Overgrowth Spectrum (PROS)
-
2024-513586-39-00
5
2025-12-10
Prostate Cancer
-
2025-521349-25-00
5
2025-12-09
Macular neovascularization secondary to age-related macular degenerati
-
2024-517573-24-00
4
2025-12-08
Colorectal cancer
-
2025-521644-37-00
4
2025-11-28
locally advanced or metastatic penile squamous cell carcinoma
-
2025-520927-26-00
5
2025-11-24
Metastatic Castration-resistant Prostate Cancer (mCRPC)
-
2024-511392-15-00
5
2025-11-20
HR+/HER2- advanced breast cancer
-
2024-520384-14-00
4
2025-11-20
Centre-involved diabetic macular edema
-
2024-520219-42-00
10
2025-11-18
ivosidenib maintenance after SOC adjuvant chemotherapy in curative mID
-
2024-512849-17-00
5
2025-11-14
Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Di
-
2024-519871-24-00
10
2025-11-11
Breast cancer
-
2024-520190-12-00
5
2025-11-10
Breast Cancer: triple negative breast cancer (TNBC) and hormone recept